Vinod Padikkal

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) is an integrated, technology-driven global CDMO platform committed to advancing therapeutics for a healthier world. Our rebranding from Suven Pharma to Cohance marks a bold new chapter—one that reflects our expanded vision and sharpened focus on collaboration and innovation. The name Cohance captures our purpose: to Collaborate with global innovators and Enhance their molecules, helping bring transformative solutions to patients and consumers worldwide. www.cohance.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

40 years of packaging excellence Manjushree Technopack Ltd. is a thought leader in rigid plastic packaging space today, in India and South Asia. Established in 1983, Manjushree Technopack started its PET packaging business in 1994 and now it has the largest capacity in both the segments – containers and PET preforms. With world class facilities and technologies, Manjushree Technopack serves every FMCG industry vertical from dairy to liquor, food products, agro chemicals, pharma, home care and personal care. Defining packaging for almost everyone, MTL has strong and long-lasting relationship with major Indian and Global brands.

ASK Investment Managers (ASK IM), registered with SEBI, is one of the largest Portfolio Management Service providers in the country today. As an approach, ASK IM believes in buying high quality businesses, to achieve superior investment results over time, through a bottom-up, long-term investment style. We currently manage both domestic and offshore clientele.

Meril’s core objective is to design, manufacture and distribute clinically relevant, state-of-the-art and best-in-class medical devices to alleviate human suffering and improve quality of life. We thus have a strong commitment towards R & D and adherence to best quality standards in Manufacturing, Scientific Communication and Distribution known today. Origin Established in 2006, Meril was launched in line with the health-care diversification plan by a large format Indian multi-national company. Disclaimer: Information on Meril Digital / Social Media platform is not intended to be a substitute for professional medical advice, diagnosis or treatment. Meril does not recommend self-management of health issues. For more information, visit: https://www.merillife.com/disclaimer

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) is an integrated, technology-driven global CDMO platform committed to advancing therapeutics for a healthier world. Our rebranding from Suven Pharma to Cohance marks a bold new chapter—one that reflects our expanded vision and sharpened focus on collaboration and innovation. The name Cohance captures our purpose: to Collaborate with global innovators and Enhance their molecules, helping bring transformative solutions to patients and consumers worldwide. www.cohance.com

Suven Pharma is a contract drug development and manufacturing (CDMO) services partner, built on more than 35+ years of research, innovation, quality, and innovative technology capability.

IIFL Home Finance is a leading, digitally-driven fintech service provider dedicated to unlocking affordable, sustainable housing and fostering all-inclusive growth. Designed to empower lower-income and economically weaker sections, we offer home loans and secured business loans with minimal documentation and approvals in just 30 minutes*. Aligned with our commitment to sustainability, we’ve made our loan processes 100% digital and paperless. Supporting the Government’s #HousingForAll mission, we provide home loans and facilitate the Government Scheme under the Pradhan Mantri Awas Yojana, making homeownership a reality for many across India. Further driving innovation in housing, we launched Kutumb—a unique platform to promote and educate about sustainable, affordable housing. Through multiple chapters across the country, we’ve also introduced the pioneering handbook Building Green: IIFL Home Loan’s Guide to Sustainable Affordable Housing. To apply and take a step towards your dream home, visit: https://bit.ly/3EKh6Pj